Australia markets open in 8 hours 29 minutes

Dermata Therapeutics, Inc. (DRMA)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3587+0.0351 (+10.85%)
At close: 04:00PM EDT
0.3360 -0.02 (-6.33%)
After hours: 06:42PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.39M
Enterprise value -5.05M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.38
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.89
52-week change 3-86.09%
S&P500 52-week change 326.27%
52-week high 32.8100
52-week low 30.2320
50-day moving average 30.3797
200-day moving average 30.6893

Share statistics

Avg vol (3-month) 3117.03k
Avg vol (10-day) 357.41k
Shares outstanding 56.66M
Implied shares outstanding 66.66M
Float 85.99M
% held by insiders 13.85%
% held by institutions 15.65%
Shares short (30 Apr 2024) 480.35k
Short ratio (30 Apr 2024) 40.47
Short % of float (30 Apr 2024) 41.25%
Short % of shares outstanding (30 Apr 2024) 41.21%
Shares short (prior month 28 Mar 2024) 4101.77k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:16
Last split date 314 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-67.36%
Return on equity (ttm)-125.96%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-7.79M
Diluted EPS (ttm)-2.6700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)7.44M
Total cash per share (mrq)1.12
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)4.91
Book value per share (mrq)1.62

Cash flow statement

Operating cash flow (ttm)-6.41M
Levered free cash flow (ttm)-3.64M